CD40 agonist mitazalimab in combination with chemotherapy

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

3mo

CD40 agonist mitazalimab in combination with chemotherapy Phase 2 Results Expected

CD40 agonist mitazalimab in combination with chemotherapy• Metastatic Pancreatic Ductal Adenocarcinoma94

Jun 1Estimated

00%

Competitive Landscape

0 competitors in Metastatic Pancreatic Ductal Adenocarcinoma

Drug Information

Target Indication

Metastatic Pancreatic Ductal Adenocarcinoma

Clinical Trial

Last updated: 1/11/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

ALLI.ST

Alligator Bioscience AB